Fresenius Covers All Bases With Akorn Acquisition And Merck Biosimilar Buy

Fresenius is shoring up its near-term US growth prospects by acquiring generics firm Akorn, as well boosting its future outlook by entering the biosimilars space via a deal with Merck KgaA.